CoChat

Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

Stuart, Darrin D., Li, Nanxin, Poon, Daniel J., Aardalen, Kimberly, Kaufman, Susan, Merritt, Hanne, Salangsang, Fernando, Lorenzana, Edward, Li, Allen, Ghoddusi, Majid, Caponigro, Giordano, Sun, Frank, Kulkarni, Swarupa, Kakar, Shefali, Turner, Nancy, Zang, Richard, Tellew, John, Pryer, Nancy · 2012 · Cancer Research
Cited by 53

The DOI matches its Crossref record.

Abstract

Selective RAF inhibitors have significant activity in patients with metastatic melanoma whose tumors express BRAFV600E. However, not all patients respond equally well to treatment and the duration of response is often limited to less than 6 months. LGX818 was developed with the hypothesis that a more potent inhibitor with excellent pharmacological properties would maximize the degree and duration of patient response. LGX818 is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E. In the A375 (BRAFV600E) human melanoma cell line LGX818 suppresses phospho-ERK (EC50 = 3 nM) leading to potent inhibition of proliferation (EC50 = 4 nM). No significant activity was observed against a panel of 100 kinases (IC50 > 900 nM) and LGX818 did not inhibit proliferation of > 400 cell lines expressing wild-type BRAF. Contributing to the high potency of LGX818 is the extremely slow off-rate from BRAFV600E which is not observed with other RAF inhibitors. In biochemical assays the dissociation half-life was >24 hours which translated into sustained target inhibition in cells following drug wash-out. Single dose PK/PD studies in human melanoma xenograft models (BRAFV600E) indicated that LGX818 treatment at oral doses as low as 6 mg/kg resulted in strong (75%) and sustained (>24 hours) decrease in phospho-MEK, even following clearance of drug from circulation. Decreases in phospho-ERK were consistent with phospho-MEK but markers of downstream transcriptional output (DUSP6 and SPRY4) appeared to provide a more sensitive measure of pathway activation. LGX818 induced tumor regression in multiple BRAF mutant human tumor xenograft models grown in immune compromised mice and rats at doses as low as 1 mg/kg. Consistent with the in vitro data, LGX818 was inactive against BRAF wild-type tumors at doses up to 300 mg/kg bid, with good tolerability and linear increase in exposure. Efficacy was also achieved in a more disease-relevant spontaneous metastatic melanoma and a model of melanoma brain metastasis. LGX818 is a potent and selective RAF kinase inhibitor with unique biochemical properties that contribute to an excellent pharmacological profile. A Phase I clinical trial in patients with BRAF mutant tumors is ongoing. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3790. doi:1538-7445.AM2012-3790

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1538-7445.am2012-3790

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 53

Metadata

Authors
Stuart, D. D., Li, N., Poon, D. J., Aardalen, K., Kaufman, S., Merritt, H., Salangsang, F., Lorenzana, E., Li, A., Ghoddusi, M., Caponigro, G., Sun, F., Kulkarni, S., Kakar, S., Turner, N., Zang, R., Tellew, J., & Pryer, N.
Venue
Cancer Research
Published
2012-04
Volume
72
Issue
8_Supplement
Pages
3790-3790
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2086010484
Cited by
53
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor. https://app.cochat.ai/papers/10.1158/1538-7445.am2012-3790
The paper
Stuart, D. D., Li, N., Poon, D. J., Aardalen, K., Kaufman, S., Merritt, H., Salangsang, F., Lorenzana, E., Li, A., Ghoddusi, M., Caponigro, G., Sun, F., Kulkarni, S., Kakar, S., Turner, N., Zang, R., Tellew, J., & Pryer, N. (2012). Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor. Cancer Research. https://doi.org/10.1158/1538-7445.am2012-3790

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.